Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Gastrointestinal tumours, colorectal 2

3115 - Efficacy and safety of Sym004 in refractory metastatic colorectal cancer with acquired resistance to anti-EGFR therapy: Results of a randomized phase II study (RP2S)

Date

11 Sep 2017

Session

Gastrointestinal tumours, colorectal 2

Presenters

Josep Tabernero

Citation

Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393

Authors

J. Tabernero1, F. Ciardiello2, C. Montagut3, C. Ding4, S. Kopetz5, T. Tuxen Poulsen6, A. Bardelli7, L. Wyrwicz8, A. Cubillo9, C. Santos10, G. Fumi11, V. Zagonel12, J. Bennouna13, S. Siena14, A. Falcone15, M. Benavent16, G. Argiles17, M. Kragh18, I.D. Horak6, M. Dvorkin19

Author affiliations

  • 1 Medical Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), 08035 - Barcelona/ES
  • 2 -, Seconda Università di Napoli, Naples/IT
  • 3 -, University Hospital del Mar, 8003 - Barcelona/ES
  • 4 -, Symphogen, Somerville, New Jersey/US
  • 5 Gi Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston/US
  • 6 -, Symphogen, Ballerup/DK
  • 7 Dept Of Oncology, IRCCs University of Torino School of Medicine, 10060 - Candiolo/IT
  • 8 Medical Oncology @ Gi Cancer Dept, M Sklodowska-Curie Memorial Cancer Center, Warsaw/PL
  • 9 Medical Oncology Department, Hospital Madrid Norte San Chinarro Centro Integral Oncologico Clara Campal, 28050 - Madrid/ES
  • 10 Medical Oncology, Institut Català d'Oncologia Hospital Duran i Reynals, 08907 - Barcelona/ES
  • 11 -, Azienda Ospedaliera S. Maria - Terni, Terni/IT
  • 12 -, Istituto Oncologico Veneto IRCCS, 35128 - Padova/IT
  • 13 -, CHU de Nantes, 44093 - Nantes/FR
  • 14 -, Niguarda Cancer Center and Università degli Studi di Milano, Milan/IT
  • 15 Oncology  , University of Pisa, 56100   - Pisa/IT
  • 16 Medical Oncology, H. U. Virgen del Rpcío, 41013 - Sevilla/ES
  • 17 Medical Oncology, Vall d'Hebron University Hospital, 08035 - Barcelona/ES
  • 18 -, Symphogen, -/DK
  • 19 Oncology, BHI of Omsk region “Clinical Oncology Dispensary”, 644013 - Omsk/RU
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3115

Background

Sym004, a mixture of 2 anti-EGFR monoclonal antibodies (mAbs), was shown to be active in a prior P1/2 trial in refractory mCRC. Due to its unique mode of action, Sym004 was developed for overcoming of acquired resistance to anti-EGFR antibodies.

Methods

254 patients (pts) were entered to an open label, multinational, 3-arm (1:1:1) RP2S comparing 2 regimens (12 mg/kg [A] or 9 mg/kg loading dose followed by 6 mg/kg [9/6; B]) of weekly Sym004 vs investigator choice (IC) of 5-FU, capecitabine, or best supportive care [C]. Standard eligibility criteria were used; pts were to be refractory to chemotherapy and have responded to, and progressed on anti-EGFR mAb-based therapy; RAS exon 2 wild type in tumour archival sample. The study was designed to detect a 3-month (M) improvement in overall survival (OS) (6 vs 9 M) between either Arm A or B and Arm C.

Results

Demographic and baseline parameters were well balanced. The Sym004 adverse event (AE) profile was typical although frequency/severity of dermatologic AEs and hypomagnesemia was higher and GI AEs appeared lower than with approved anti-EGFR mAbs. Arm B was better tolerated than Arm A. OS in the ITT population and exploratory subgroups are presented. The primary outcome of the study was negative due to unexpected outcomes of Arm C. Arm B (9/6 mg dose) was not only better tolerated over 12/6 mg (Arm A), but also was associated with improved survival. Biomarker-specific analyses evaluating pts with double-negative (DN) (no RAS mutant allele frequency >20% in circulating tumor [ct]DNA; no BRAF V600E) or triple-negative (TN) (DN + no EGFR extracellular domain mutation in ctDNA) mCRC demonstrated markedly prolonged survival and established the 9/6 regimen as well-tolerated and active in DNmCRC (OS increased 3.5 M) and TNmCRC (OS increased 5.5 M).Table: 478O

PopulationArm AArm BArm C
ITT N = 2547.9a (6.5, 9.9)b N = 8310.3 (9.0, 12.9) N = 869.6 (8.3, 12.2) N = 85
US&EUc N = 2247.7 (6.1, 11.3) N = 759.9 (8.0, 12.8) N = 748.5 (6.8, 10.2) N = 75
US&EU with biomarker data N = 1937.7 (5.5, 11.3) N = 709.9 (7.1, 12.9) N = 678.5 (6.4, 9.9) N = 56)
US&EU with DNmCRC N = 170 (88%)d8.9 (6.2, 12.4) N = 6211.9 (9.7, 13.8) N = 578.4 (6.4, 10.0) N = 51
US&EU with TNmCRC N = 131 (68%)d10.6 (6.8, 13.1) N = 4712.8 (9.7, 14.7) N = 467.3 (6.3, 8.8) N = 38

amedian survival in M

b95% confidence intervals

cthe subgroup analyses excluded pts due to different medical practice

dwith biomarker data

Conclusions

Although the study was negative in ITT population, treatment with Sym004 was associated with remarkable response when compared with any 4th-line treatment of mCRC. The promising results in the molecularly selected population provide guidance to design a pivotal ctDNA-guided pivotal trial in EGFR inhibitor refractory mCRC.

Clinical trial identification

NCT02083653 or EMR200637-002

Legal entity responsible for the study

Symphogen

Funding

Symphogen

Disclosure

J. Tabernero: Advisory boards: Amgen, Bayer, Boehringer Ingelheim, Celgene, Chugai, Genentech, Lilly, MSD, Merck Serono, Novartis, Pfizer, Roche, Sanofi, Symphogen, Taiho, Takeda. F. Ciardiello: Advisory boards: Roche, Merck, Lilly, BMS, Pfizer, Amgen, Bayer. C. Montagut: Advisory boards: Amgen, Bayer, Merck Serono, Sanofi, Symphogen. C. Ding, T. Tuxen Poulsen, M. Kragh, I.D. Horak: Employee of Symphogen. S. Kopetz: Advisory boards: Amgen, Merrimack, Bayer, Sanofi, Array BioPharma, Genentech, Molecular Match, Symphogen, Guardant Health, EMD Serono, Merck. V. Zagonel: Advisory boards: Celgene, Bayer, Roche, Amgen, Novartis, Pfizer. J. Bennouna: Honoraria: Roche, Boehringer Ingelheim, AstrZeneca, Shire, MSD, BMS; consulting or advisory role: Roche, Boehringer Ingelheim, AstraZeneca, Shire, MSD, BMS. S. Siena: Advisory boards: Amgen, Roche, Bayer, Merck-Serono, Sanofi, Merrimack. A. Falcone: Advisory boards and research grants to Institution: Amgen, Merck, Roche, Bayer, Servier, Lilly, Sanofi. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.